mercredi 29 août 2018

Onco Actu du 29 août 2018


1. Biologie

Mass. General team finds how NF-2 gene mutations make cells hyper-responsive to growth factor signaling [Mass. General Hospital]

In a Twist, Scientists Find Cancer Drivers Hiding in RNA, Not DNA [Memorial Sloan Kettering Cancer Center]

How Do Fruit Flies Grow Legs? Solving a Molecular Mystery [Columbia University]

New Study Explains Why Genetic Mutations Cause Disease in Some People but Not in Others [Columbia University]

2.10 Etiologie - Alcool

Study Causes Splash, but Here’s Why You Should Stay Calm on Alcohol’s Risks [NY Times]

3.3 Prévention - Vaccins

One more time: HPV vaccination is not associated with primary ovarian insufficiency [Respectful Insolence]

4.9 Dép., diag. & prono. - Sein

A New Way to Detect Breast Cancer [NY Times]

5.1 Traitements - Pré-clinique

Stem cells show promise as drug delivery tool for childhood brain cancer [UNC School of Medicine]

5.10 Traitements - Essais

Researchers to Test Novel Drug Combination Against Toughest Breast Cancers [UC San Diego]

Evaluation of Clinical Trial Costs and Barriers to Drug Development [Igea Hub]

Researchers find a way to mimic clinical trials using genetics [MIT Technology Review]

5.12 Immunothérapies

Molecular Insights in Clinical Responses to PD-1 Inhibition in Metastatic Gastric Cancer [ESMO]

5.12.1 Immunothérapies - partenariats

Affimed lands big, backloaded immunotherapy deal with Genentech, sending its stock into overdrive [FierceBiotech]

5.12.2 Immunothérapies - CAR-T, thérapies cellulaires

Gilead CAR-T drug Yescarta turned away by NICE cost-effectiveness watchdogs [FiercePharma]

Feedback encouraged to allow use of life extending treatment on NHS for those with blood cancer [NICE]

UK rejects Gilead's CAR-T cancer cell therapy as too expensive [Reuters]

Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma after 2 or more systemic therapies [NICE]

5.3.4 Traitements - AMM (FDA, EMA,...)

European Commission approves Novartis combination therapy Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600 mutation-positive melanoma [Novartis]

Vyxeos® Receives Marketing Authorisation in the European Union for Treatment of Certain Types of High-Risk Acute Myeloid Leukaemia [Jazz Pharmaceuticals]

5.6 ESMO

Men and women are different: Why medical oncology needs to restate the obvious [ESMO Press Release]

6.1 Observation

CDC: Mouth area now most common site of HPV-linked cancer [University of Minnesota]

6.10 Politiques

A no-deal Brexit will betray British science [The Guardian]

Help to shape policy with your science [Nature]

6.11 Patients

The realities of cancer - Mental health issues and changes to energy levels top concerns among cancer patients [Cancer Research UK]

6.6 Publications

Best Match: New relevance search for PubMed [PLoS Biology]

6.7 DMP, Big Data & applis

Integra Connect Becomes CancerLinQ Platform’s First Certified Electronic Health Record [ASCO]

6.9 Controverses

Opinion: Expansion fever and soft money plague the biomedical research enterprise [PNAS]